Autolomous, a developer of critical manufacturing management systems for cell and gene therapies, and BioCentriq, a clinical-phase Cell Therapy contract development and manufacturing organization (CDMO) that recently completed its latest round of fundraising, have partnered to digitize and accelerate process development and manufacturing activities.
 
Autolomous’ autoloMATE solution, a no-code, fully cloud-native software platform, will equip BioCentriq with a pivotal tool to enhance efficiency while upholding high standards of quality and data integrity in their work.
 
BioCentriq will leverage the autoloMATE platform to streamline its process development operations and enhance client experience, utilizing its intuitive configuration and execution services. This partnership aims to ultimately accelerate batch delivery, ensuring patients have faster access to cutting-edge cell therapies.
 
“Autolomous’ autoloMATE platform will transform our operations, replacing paper-based systems with a purpose-built digital solution,” said David Smith, Ph.D., Vice President of Development at BioCentriq. “By streamlining data exchange throughout the development and manufacturing processes, we will be able to enhance operational efficiency and flexibility, de-risk timelines and ultimately deliver life-changing therapies to patients more quickly.”
 
“BioCentriq’s unwavering dedication to pioneering new paths in the medical field, coupled with their spirit of collaboration, perfectly aligns with our vision,” said Alexander Seyf, CEO and Co-founder of Autolomous. “The distinct capabilities of our platform are meticulously engineered to navigate and surmount the intricacies of cell and gene therapy development and production. Through our partnership, we are poised to accelerate towards a future where life-saving therapies are within reach of every patient in need, marking a significant leap forward in healthcare innovation.”